|  |  |
| --- | --- |
|   | **XX Annual Conference “Hepatology Today 2015”** |
|   | **Programme** |
|   | **the 30th of March - 1st of April 2015** |
|   | **AMBER PLAZA, Krasnoproletarskaya street bldg. 36, Moscow** |
|   |   |
|  |  |
|  | **First day** **March 30th, 2015** |
| **08.00 - 08.30** | **Topical Lecture. "Drug induced liver disease"**  |
|  | **(supported by Sun Pharmaceutical Industries Ltd.)**  |
|   | **Deepak N. Amarapurkar (Mumbai, India)** |
| **08.30 - 10.00** | **Clinical symposium "Pathogenesis and mechnisms of liver injury in NAFLD and NASH"** |
|  | **(supported by "Sanofi")** |
|  | ***Chairs: V. T. Ivashkin, L. K. Palgova*** |
| 08.30 - 08.40 | Variety of liver diseases in Russian Federation. |
|   | **V. T. Ivashkin (Moscow, Russia)** |
| 08.40 - 09.00 | Lipid metabolism and signaling pathways in case of injury |
|   | **V. T. Ivashkin, K. V. Ivashkin (Moscow, Russia)** |
| 09.00 - 09.20 | Mechanism of hepatocellular injury in NASH |
|   | **E. N. Shirokova (Moscow, Russia)** |
| 09.20 - 09.40 | Different masks of NAFLD. |
|   | **L. К. Palgova (Saint Petersburg, Russia)** |
| 09.40 - 10.00 | Therapy of NAFLD |
|   | **V. T. Ivashkin (Moscow, Russia)** |
| **10.00 - 10.30** | **Coffee-break** |
| **10.30 - 12.00** | **EASL/RSLS Symposium "NAFLD: a broad spectrum of clinical manifestations"** |
|  | ***Chairs: M. Peck-Radosavljevic, C. S. Pavlov*** |
| 10.30 - 10.50 | NAFLD and Hepatocellular Carcinoma |
|   | **Markus Peck-Radosavljevic (Vienna, Аustria)**  |
| 10.50 - 11.10 | Alcoholic and non-alcoholic steatohepatitis |
|   | **Cecilia Maria Pereira Rodrigues (Lisbon, Portugal)** |
| 11.10 - 11.30 | Chronic hepatitis C and lipids metabolism disturbances |
|   | **M. Peck-Radosavljevic (Vienna, Аustria)** |
| 11.30 - 12.00 | *Discussion* |
| **12.00 - 13.00** | **Scientific session. "Viral hepatitis (clinical aspects)"** |
|  | ***Chairs: O. О. Znoyko, V. G. Morozov*** |
| 12.00 - 12.15 | Nutritive support of patients with liver cirrhosis: experience of using peptide amino-acid complex derived from silk protein |
|   | **V. G. Morozov (Samara, Russia)** |
| 12.15 - 12.30 | Clinical relevance of recombinant HCV variants |
|   | **O. О. Znoyko, О. V. Каlinina, А. N. Коzina (Moscow, Russia)** |
| 12.30 - 12.45 | Treatment of CHC in methadon-addicted patients |
|   | **Мarieta Simonova (Sofia, Bulgaria)** |
| 12.45 - 13.00 | Liver fibrosis assessment during an era of application of antiviral -HCV/HBV drugs |
|   | **Mona Munteanu (Paris, France)** |
| **13.00 - 14.00** | **Coffee-break** |
| **14.00 - 14.30** | **Ceremonial session dedicated to the 20th anniversary of the congress "Hepatology Today"** |
| **14.30 - 16.00** | **Clinical symposium. "Hepatitis C- Real solutions of today"**  |
|  | **(supported by Janssen, pharmaceutical company of "Johnson & Johnson")** |
|  | ***Chairs: V. T. Ivashkin, N. D. Uschuk*** |
| 14.30 - 14.50 | HCV life-cycle |
|   | **V. T. Ivashkin (Moscow, Russia)** |
| 14.50 - 15.10 | Relapse after dual antiviral therapy (clinical case) |
|   | **M. V. Maevskaya (Moscow, Russia)** |
| 15.10 - 15.30 | Indications for antiviral therapy on a basis of non-invasive assessment’s criteria for fibrosis |
|   | **C. S. Pavlov (Moscow, Russia)** |
| 15.30 - 15.50 | Clinical case: Maintaining the patient according to the Russian clinical guidelines |
|   | **E. A. Klimova (Moscow, Russia)** |
| 15.50 - 16.00 | *Discussion* |
| **16.00 - 17.30** | **Clinical symposium. "** **Chronic viral hepatitis and liver cirrhosis"** |
|  | **(supported by "Bristol Mayer Squibb")** |
|   | ***Chair: E. A. Klimova*** |
| 16.00 - 16.20 | How do we understand “F4 fibrosis”? Is liver cirrhosis reversible? |
|   | **C. S. Pavlov (Moscow, Russia)** |
| 16.20 - 16.40 | Liver cirrhosis in 2015  |
|   | **V. T. Ivashkin (Moscow, Russia)** |
| 16.40 - 17.00 | Liver cirrhosis reversibility in chronic hepatitis |
|   | **D. T. Abdurahmanov (Moscow, Russia)** |
| 17.00 - 17.20 | New strategies of chronic hepatitis C treatment at all disease stages |
|   | **M. V. Maevskaya (Moscow, Russia)** |
| 17.20 - 17.30 | *Discussion* |
| **17.30 - 17.45** | **Coffee-break** |
| **17.45 - 18.15** | **Scientific session. "Clinical hepatology"** |
|  | ***Chair: M. V. Maevskaya*** |
| 17.45 - 18.00 | Resustance to protease inhibitors and antiviral therapy efficacy in chronic hepatitis C patients |
|   | **S. N. Batskikh (Moscow, Russia)** |
| 18.00 - 18.15 | Some aspects of differential diagnosis and prognosis in autoimmune liver diseases |
|   | **К. L. Raykhelson, N. V. Marchenko, V. E. Karev, A. Yu. Baranovsky (Saint Petersburg, Russia)** |

|  |  |
| --- | --- |
|  | **Second day** **March 31st, 2015** |
| **08.00 - 09.00** | **Clinical symposium. "Severe forms of alcoholic and non-alcoholic liver disease"** |
|  | **(supported by Abbott Laboratories)** |
|  | ***Chairs: V. T. Ivashkin, M. V. Maevskaya*** |
| 08.00 - 08.10 | Introduction: Benefits of Ademetionine therapy |
|   | **V. T. Ivashkin, K. V. Ivashkin (Moscow, Russia)** |
| 08.10 - 08.30 | Differential diagnosis between liver function decompensation and “Acute on chronic liver failure” in patient with alcoholic hepatitis (clinical case) |
|   | **E. A. Fedosina (Moscow, Russia)** |
| 08.30 - 08.50 | NAFLD and risk of liver cirrhosis |
|   | **Е. N. Bessonova (Ekaterinburg, Russia)** |
| 08.50 - 09.00 | Clinical tasks and conclusion |
|   | **М. V. Маevskaya (Moscow, Russia)** |
| **09.00 - 10.30** | **EASL Master class** |
|  | ***Chair: C. S. Pavlov*** |
| 09.00 - 09.30 | EASL State-of-the-art-Lecture. "Imagine procedures in NAFLD: Ultrasound, CT scan, NMR, Proton spectroscopy" |
|   | **Valerie Vilgrain (Clichy, France)** |
| 09.30 - 10.00 | EASL State-of-the-art-Lecture. "Noninvasive evaluation of NAFLD\NASH" |
|   | **Lauren Castera (Clichy, France)** |
| 10.00 - 10.30 | Master class lecture. "Chronic hepatitis C 2015" |
|   | **Markus Peck-Radosavljevic (Vienna, Аustria)** |
| **10.30 - 11.00** | **Coffee-break** |
| **11.00 - 11.30** | **Lecture. "Epydemyology of NAFLD in Europe and Russia"** |
|  | ***Chair: L. K. Palgova*** |
|  | **V. V. Tsukanov (Krasnoyarsk, Russia)** |
| **11.30 - 12.00** | **Symposium. "Ursodeoxycholic acid in NAFLD treatment"** |
|  | **(supported by "PRO.MED.CS Praha a.s.")** |
|  | ***Chair: V. T. Ivashkin*** |
| 11.30 - 11.45 | The combined hypolipidemic therapy in patients with cardiovascular diseases and liver pathology. Results from the RACURS trial |
|   | **S. Yu. Marcevich (Moscow, Russia)** |
| 11.45 - 12.00 | NAFLD and UDCA –Results from the RACURS trial |
|   | **M. Yu. Nadinskaya (Moscow, Russia)** |
| **12.00 - 12.30** | **Symposium. "Anti-HCV treatment based on pegylated interferon alfa: main principles"** |
|  | **(supported by "ROCHE")** |
|  | **E. Z. Burnevich (Moscow, Russia)** |
| **12.30 - 14.00** | **RSLS clinical symposium. "New strategies of HCV treatment in transplanted patients (clinical cases)"** |
|  | ***Chairs: S. V. Gotye, V. T. Ivashkin, A. G. Chuchalin, N. D. Yuschuk*** |
| 12.30 - 12.50 | CHC in lung transplant recipient (clinical case) |
|   | **N. A. Karchevskaya, Е. А. Tarabrin (Moscow, Russia)** |
| 12.50 - 13.10 | CHC in lung transplant recipient (clinical case) |
|   | **I. N. Tihonov, V. Yu. Syutkin et al. (Moscow, Russia)** |
| 13.10 - 13.30 | CHC in lung transplant recipient (clinical case) |
|   | **М. L. Zubkin (Moscow, Russia)** |
| 13.30 - 13.50 | Sofosbuvir and Simeprevir in successful hepatitis C treatment after liver transplantation in patient with IgA-nephropathy receiving long term hemodialysis |
|   | **E. B. Yaroshenko (Moscow, Russia)** |
| 13.50 - 14.00 | *Discussion* |
| **14.00 - 15.00** | **Coffee-break** |
| **15.00 - 16.00** | **Young Investigator Award** ***Chairs: V. T. Ivashkin, C. S. Pavlov***  |
| 15.00 - 15.15 | First place winner: "Polymorphism of RAAS genes and liver fibrosis progression in patients with HCH" |
|   | **O.V. Taratina (Moscow, Russia)** |
| 15.15 - 15.30 | Second place winner: "Cirrhotic cardiomiopathy regression after liver transplantation" |
|   | **Yu. O. Malinovskaya (Moscow, Russia)** |
| 15.30 - 15.45 | Third place winner: "Non-invasive assesment of portal hypertation using TE" |
|   | **E. O. Lusina (Moscow, Russia)** |
| 15.45 - 16.00 | **Winners Award** |
| **16.00 - 17.00** | **Clinical symposium. "Are there any methods to reduce the mortality rate from alcohol related diseases in Russia?"** |
|  | **(supported by "Lundbeck")** |
|  | ***Chairs: V. T. Ivashkin, S. V. Plyusnin, P. P. Ogurtsov*** |
| 16.00 - 16.20 | Physician's role in alcoholism treatment. Simple skills are of great value |
|   | **Yu. P. Sivolap (Moscow, Russia)** |
| 16.20 - 16.40 | Alcohol-related injury in clinical practice |
|   | **P. P. Ogurtsov (Moscow, Russia)** |
| 16.40 - 16.55 | Complex measures in reducing mortality associated with alcohol abuse |
|   | **S. V. Plyusnin (Moscow, Russia)** |
| 16.55 - 17.00 | *Discussion* |
| **17.00 - 17.30** | **Clinical symposium (supported by "Polysan")** |
|  | Mitochondrial dysfunction in metabolic syndrome |
|  | **S. V. Okovitiy (Saint Petersburg, Russia)** |
| **17.30 - 18.00** | **Clinical symposium (supported by "Biocad")** |
|  | Cepeginterferon alfa-2b efficacy in different groups of HCV-infected patients |
|  | **A. A. Shuldyakov (Saratov, Russia)** |
| **18.00 - 18.15** | **Bayer Coffee-break** |
| **18.15 - 19.15** | **Clinical symposium. "Hepatocellular carcinoma: to find and neutralize"**  |
|  | **(supported by "Bayer")** |
|  | ***Chairs: V. V. Breder, C. S. Pavlov, B. K. Medvedeva*** |
| 18.15 - 18.20 | Clinical case with patient's participation |
|   | **V. V. Breder (Moscow, Russia)** |
| 18.20 - 18.30 | Groups of HCC risk, screening methods |
|   | **M. V. Maevskaya (Moscow, Russia)** |
| 18.30 - 18.50 | Imaging techniques of choice in HCC diagnostics |
|   | **B. К. Меdvedeva (Moscow, Russia)** |
| 18.50 - 19.00 | Morphological features of HCC |
|   | **К. А. Моroz (Moscow, Russia)** |
| 19.00 - 19.15 | Determining HCC Management |
|   | **V. V. Breder (Moscow, Russia)** |

|  |  |
| --- | --- |
|  | **Третий день || 01.04.2015** |
| **08.00 - 09.00** | **Scientific session. "Hepatitis, cirrhosis, fundamental research in hepatology"** |
|  | ***Chairs: C. S. Pavlov, I. G. Bakulin*** |
| 08.00 - 08.15 | Risk factors for portal vein thrombosis in cirrhotic patients |
|   | **M. Yu. Nadinskaya, V. E. Bugayov (Moscow, Russia)** |
| 08.15 - 08.30 | Patient's gender as a risk factor for hepatocellular carcinoma |
|   | **A. V. Shaposhnikov (Rostov-on-Don, Russia)** |
| 08.30 - 08.45 | Results of efficacy trial of Cepeginterferon alfa-2b in comparison with PegINF alfa-2b in chronic hepatitis C patients |
|   | **I. Yu. Pirogova (Chelyabinsk, Russia)** |
| 08.45 - 09.00 | *Discussion* |
| **09.00 - 09.45** | **Discussion on clinical guidelines** |
|  | ***Chairs: E. N. Shirokova, V. T. Ivashkin*** |
| 09.00 - 09.20 | Eosophageal varices bleeding |
|   | **E. A. Kitsenko (Moscow, Russia)** |
| 09.20 - 09.25 | *Discussion* |
| 09.25 - 09.40 | NAFLD |
|   | **E. N. Shirokova (Moscow, Russia)** |
| 09.40 - 09.45 | *Discussion* |
| **09.45 - 10.45** | **Clinical symposium. "New Interferon-Free Regimens in Treatment of Hepatitis C Virus" (supported by "AbbVie")** |
|  | ***Chair: V. T. Ivashkin*** |
| 09.45 - 10.05 | Interferon-free regimens: expected changes in strategy and tactics of anti-HCV treatment |
|   | **E. Z. Burnevich (Moscow, Russia)** |
| 10.05 - 10.25 | "Difficult patient" and "3D-regimen»" |
|   | **M. V. Maevskaya (Moscow, Russia)** |
| 10.25 - 10.45 | *Discussion* |
| **10.45 - 11.15** | **Coffee-break** |
| **11.15 - 12.15** | **Clinical symposium. "Boceprevir - indications for use"**  |
|  | **(supported by "MSD")** |
|  | ***Chair: M. V. Maevskaya*** |
| 11.15 - 11.35 | Management of patients in the context of limited resources |
|   | **P. P. Ogurtsov (Moscow, Russia)** |
| 11.35 - 11.55 | Boceprevir is still in play |
|   | **E. Z. Burnevich (Moscow, Russia)** |
| 11.55 - 12.15 | *Discussion* |
| **12.15 - 13.15** | **Basic Science Session. "Cardiovascular pathology in liver diseases, metabolic disorders"** |
|  | ***Chairs: O. M. Drapkina, N. I. Geyvandova*** |
| 12.15 - 12.30 | Prognostic role of galectin-3 in patients with metabolic syndrome and nonalcoholic fatty liver disease |
|   | **T. A. Deeva, O. M. Drapkina, V. T. Ivashkin (Moscow, Russia)** |
| 12.30 - 12.45 | Comparative analysis of left ventricular structure and geometry changes in patients with chronic viral hepatitis and viral liver cirrhosis |
|   | **Т. S. Моrozova, I. F. Grishina, I. А. Gurikova (Ekaterinburg, Russia)** |
| 12.45 - 13.00 | Impact of L-Arginine L-glutamate on serum vasoactive substances level in cirrhotic patients |
|   | **Е. S. Sirchak (Uzhgorod, Russia)** |
| 13.00 - 13.15 | Serum Vitamin D level in chronic hepatitis C patients |
|   | **N. I. Geyvandova (Stavropol, Russia)** |
| **13.15 - 13.45** | **Clinical symposium (supported by "R-Pharm")** |
|  | **Narlaprevir – a new NS3/4A-protease inhibitor: look into the near future** |
|  | **E. Z. Burnevich (Moscow, Russia)** |
| **13.45 - 14.15** | **Coffee-break** |
| **14.15 - 14.45** | **Clinical symposium. "Liver cirrhosis complications"** |
|  | **(supported by "ALFA WASSERMANN")** |
|  | ***Chair: V. T. Ivashkin*** |
| 14.15 - 14.35 | Infections in liver cirrhosis |
|   | **M. V. Maevskaya (Moscow, Russia)** |
| 14.35 - 14.45 | *Discussion* |
| **14.45 - 15.15** | **Bicyclol in treatment of adult chronic hepatitis C patients (results of comparative randomized** **double-blind placebo-controlled trial)**  |
|  | **(supported by "Beijing Union Pharmaceutical Factory")** |
|  | **N. I. Geyvandova (Stavropol, Russia)** |
| **15.15 - 16.15** | **Clinical symposium. "Proton pump inhibitors in liver diseases"** |
|  | **(supported by Janssen, pharmaceutical company of "Johnson & Johnson")** |
|  | ***Chairs: V. T. Ivashkin, I.V. Maev, Т. L. Lapina*** |
| 15.15 - 15.30 | Upper gastrointestinal tract erosive-ulcerative lesions in liver diseases without portal hypertension |
|  | **M. S. Zharkova (Moscow, Russia)** |
| 15.30 - 15.45 | Management of upper gastrointestinal tract H.p.-assosiated diseases |
|   | **I.V. Maev (Moscow, Russia)** |
| 15.45 - 16.00 | Clinical case: chronic hepatitis C patient with duodenal ulcer |
|   | **V. D. Lunkov (Moscow, Russia)** |
| 16.00 - 16.15 | Drug interactions |
|   | **S. Yu. Serebrova (Moscow, Russia)** |
| **16.15** | **Farewell** |